Curbing C. difficile's toxin productionSeptember 06, 2007As if being admitted to the hospital weren't bad enough, patients, once admitted, are at higher risk of becoming infected with a "superbug" bacterium, Clostridium difficile (C. difficile). The toxins produced by C. difficile kill human intestinal cells by causing them to burst open, allowing the bacteria to use them as fuel. This results in severe diarrhea and, in rare cases, death. Abraham "Linc" Sonenshein, PhD, and colleagues from the Department of Molecular Biology and Microbiology at the Tufts University School of Medicine (TUSM) and the Sackler School of Graduate Biomedical Sciences at Tufts, have discovered how a protein called CodY regulates the genes that control production of the dangerous toxins. Understanding the relationship between CodY and C. difficile is an important step toward the development of a drug that may prevent hospital patients from falling ill. "The C. difficile bacteria only produce toxins when they are in need of food," explains Sonenshein, professor of microbiology at TUSM and corresponding author on the paper to be published in Molecular Microbiology. "We found that the CodY protein, in essence, monitors the hunger level of C. difficile, preventing toxin production when the bacteria have enough to eat." Sonenshein, along with first author Sean Dineen, PhD, and other Tufts colleagues developed a series of experiments to investigate the importance of CodY and how this protein communicates to bacteria that it is time to search for new sources of food. The researchers first developed a mutant strain of C. difficile bacteria that does not make the protein CodY, and compared the amount of toxin produced by the mutant strain of bacteria to the amount of toxin produced by normal bacteria. The mutant strain produced much higher levels of toxin. The presence of CodY seems to tell the bacterial cells that they are well-fed and there is no reason to make toxin that kills intestinal cells for fuel. Lack of CodY activity, however, indicates to the bacteria that they are lacking key nutrients and that it is time to make the toxins they need to get food from the host cells.
To determine how CodY tells the bacteria not to make toxins, Sonenshein and colleagues removed DNA from the bacteria, and observed the interaction of the DNA and the CodY protein in vitro. They found that CodY targeted the region of the bacterial chromosome that includes the toxin genes. "When CodY senses that the cell has enough nutrients, it binds to this gene region, and prevents the bacterium from making toxin," says Sonenshein. "Conversely, when food is scarce, the CodY protein does not bind to these genes, allowing C. difficile to make the toxins needed to attack intestinal cells." Knowing what turns on, and more importantly, what turns off the toxin-producing genes in C. difficile opens the door for treatment and prevention options. "It is possible that, based on our findings, a new drug could be developed that would trick CodY into thinking there is enough fuel for the bacteria, causing CodY to remain bound to the toxin gene region and thus suppressing toxin production." Tufts University, Health Sciences | |||||||||||||||||||||
|
Related Clostridium Difficile Current Events and Clostridium Difficile News Articles Is re-emerging superbug the next MRSA? Loyola physicians warn little-known bacteria Clostridium difficile next emerging disease threat, killing 1,000s in the United State. Advances in C. difficile research New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen. The balance shifts The risk of contracting a Clostridium difficile infection following operations for which a "prophylactic" antibiotic is given to prevent infection is 21 times greater now than it was just a decade ago, according to researchers from the University of Sherbrooke in Canada. They report their findings in the June 15 issue of Clinical Infectious Diseases, currently available online. ASGE issues updated infection control guidelines for gastrointestinal endoscopy The American Society for Gastrointestinal Endoscopy (ASGE) has updated its infection control guidelines regarding gastrointestinal (GI) endoscopy. UV lotion lights the way to cleaner facilities A team of Canadian scientists using a lotion which glows under ultraviolet light have shown that up to a third of patient toilets are not properly cleaned. Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. MRSA in hospital intensive care -- what's growing where? Researchers are finding out which bugs grow in intensive care units to develop a novel sampling regime that would indicate the threat of MRSA and other superbugs in the environment, scientists heard today (Monday 31 March 2008) at the Society for General Microbiology's 162nd meeting being held this week at the Edinburgh International Conference Centre. APIC launches first national C. difficile prevalence study The Association for Professionals in Infection Control and Epidemiology (APIC) today announced a detailed strategy to combat Clostridium difficile-associated disease (CDAD). Confronting the challenge of antimicrobial resistance Drug resistance is making many diseases increasingly difficult--and sometimes impossible--to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States. More Clostridium Difficile Current Events and Clostridium Difficile News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||